This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pollack, I. F. Articles by Curran, D. P. Search for Related Content PubMed PubMed Citation Articles by Pollack, I. F. Articles by Curran, D. P.

Potent Topoisomerase I Inhibition by Novel Silatecans Eliminates Glioma Proliferation in Vitro and in Vivo¹

Department of Neurosurgery, Children’s Hospital of Pittsburgh and University of Pittsburgh Cancer Institute Brain Tumor Center [I. F. P., M. E.], University of Pittsburgh School of Medicine [I. F. P., M. E.], and Department of Chemistry, University of Pittsburgh [I. F. P., M. E., D. B., D. P. C.], Pittsburgh, Pennsylvania 15213-2583, and Experimental Therapeutics Program, Markey Cancer Center, University of Kentucky Colleges of Pharmacy and Medicine, Lexington, Kentucky 40506-0286 [T. G. B., J. T. S.]

Although topoisomerase inhibitors, such as camptothecin and topotecan, have been widely used in the treatment of nonglial tumors, their application for gliomas has been limited by poor efficacy relative to toxicity that may in part reflect limited bioavailability and blood stability of these agents. However, the potential promise of this class of agents has fostered efforts to develop new, more potent, and less toxic inhibitors that may be clinically relevant. Using a cascade radical annulation route to the camptothecin family, we developed a series of novel camptothecin analogues, 7-silylcamptothecins ("silatecans"), that exhibited potent inhibition of topoisomerase I, dramatically improved blood stability, and sufficient lipophilicity to favor blood-brain barrier transit. We explored the efficacy of a series of these agents against a panel of five high-grade glioma cell lines to identify a promising compound for further preclinical testing. One of the most active agents in our systems (DB67) inhibited tumor growth in vitro with an ED₅₀ ranging between 2 and 40 ng/ml, at least 10-fold more potent than the effects observed with topotecan, and at least comparable with those of SN-38, the active metabolite of CPT-11. Because DB67 also exhibited the highest human blood stability of any of the agents examined, this agent was then selected for in vivo studies. A dose-escalation study of this agent in a nude mouse U87 glioma model system demonstrated a concentration-dependent effect, with tumor growth inhibition at day 28 postimplantation (the day control animals began to require sacrifice because of large tumor size) of 61 ± 7% and 73 ± 3% after administration of DB67 doses of 3 and 10 mg/kg/day, respectively, for 5 days beginning on postimplantation day 7. Animals that continued treatment with 10 mg/kg/day in three additional 21-day cycles all remained progression free after >90 days of follow-up but later developed enlarging tumors after treatment was stopped. However, a slightly higher dose (30 mg/kg/day) induced complete tumor regression after only two cycles in all study animals and was effective even if treatment was delayed until large, bulky tumors had developed. Application of the 30 mg/kg/day dose to treat established intracranial glioma xenografts led to long-term (>90 day) survival in six of six animals, whereas all controls died of progressive disease (P < 0.00001). No apparent toxicity was encountered in any of the treated animals. In summary, the present studies indicate that silatecans may hold significant promise for the treatment of high-grade gliomas and provide a rationale for proceeding with further preclinical evaluation of their efficacy and safety versus commercially available camptothecin derivatives.

This article has been cited by other articles:

				A. Y. Chen, S.-J. Shih, L. N. Garriques, M. L. Rothenberg, M. Hsiao, and D. P. Curran Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer Mol. Cancer Ther., February 1, 2005; 4(2): 317 - 324. [Abstract] [Full Text] [PDF]

				M. A. Burg, K. Jensen-Pergakes, A. M. Gonzalez, P. Ravey, A. Baird, and D. Larocca Enhanced Phagemid Particle Gene Transfer in Camptothecin-treated Carcinoma Cells Cancer Res., February 1, 2002; 62(4): 977 - 981. [Abstract] [Full Text] [PDF]

				M. De Cesare, G. Pratesi, P. Perego, N. Carenini, S. Tinelli, L. Merlini, S. Penco, C. Pisano, F. Bucci, L. Vesci, et al. Potent Antitumor Activity and Improved Pharmacological Profile of ST1481, a Novel 7-substituted Camptothecin Cancer Res., October 1, 2001; 61(19): 7189 - 7195. [Abstract] [Full Text] [PDF]

				M. A. Watson, A. Perry, V. Budhjara, C. Hicks, W. D. Shannon, and K. M. Rich Gene Expression Profiling with Oligonucleotide Microarrays Distinguishes World Health Organization Grade of Oligodendrogliomas Cancer Res., March 1, 2001; 61(5): 1825 - 1829. [Abstract] [Full Text]